www.hivandhepatitis.com

Coverage of the 2017 Harm Reduction International Conference

Details
Category: HIV Treatment
Published on Wednesday, 31 May 2017 00:00
Written by HIVandHepatitis.com
  • Print

HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.

Full coverage listing

HR17 website

5/31/17

alt

Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections

Details
Category: HIV Treatment
Published on Sunday, 16 April 2017 00:00
Written by HIVandHepatitis.com
  • Print

HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.

Full coverage listing by topic

CROI website

4/16/17

alt

CROI 2016: HIV/HBV Coinfection Linked to Worse Immune Recovery and Death

Details
Category: HIV/HBV Coinfection
Published on Wednesday, 06 April 2016 00:00
Written by Liz Highleyman
  • Print

HIV-positive people with hepatitis B virus (HBV) coinfection had impaired CD4 cell recovery after starting antiretroviral (ART) and a higher risk of death than those without hepatitis B, but use of ART regimens containing tenofovir significantly reduced mortality, according to a study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)in Boston.

alt

Read more:

CROI 2016: Studies Probe Retention in Care for HIV+ Women Who Start ART During Pregnancy

Details
Category: Pregnancy & HIV MTCT
Published on Tuesday, 12 April 2016 00:00
Written by Carole Leach-Lemens
  • Print

Engaging lay counselors to provide a combination package of evidence-based interventions in Nyanza, Kenya, and addressing partner disclosure, as well as pre-treatment education about the benefits of antiretroviral therapy (ART) for maternal and child health in Malawi’s Option B+ program improved retention in care and reduced loss to follow-up of mothers with HIV and their infants, studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) show.

alt

Read more:

CROI 2016: Hepatitis C [VIDEO]

Details
Category: HCV Treatment
Published on Wednesday, 06 April 2016 00:00
Written by HIVandHepatitis.com
  • Print

New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.

 

Read more:

More Articles...

  1. CROI 2016: Advances in Hepatitis C Research [VIDEO]
  2. CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention
  3. CROI 2016: Partner Notification of HIV Status Is Feasible and Effective In African Settings
  4. CROI 2016: VRC01 Antibody Delays But Does Not Prevent HIV Rebound After ART Interruption
  5. CROI 2016: Primary Care Providers Can Successfully Treat People with Hepatitis C
  6. CROI 2016: Dose-Finding Trials of Antibody-Based Drugs for HIV Prevention To Start Soon
  7. CROI 2016: Personalized Counseling Improves Rate of Entry into HIV Care
  8. CROI 2016: More People with HIV Are Achieving Viral Suppression in U.S.
  9. CROI 2016: Antidepressant Improves HIV-Related Cognitive Impairment
  10. CROI 2016: Women and African Americans with HIV Have a Higher Risk of Stroke
  11. CROI 2016: Combination Inhibitor BMS-986197 Demonstrates Good Anti-HIV Activity in Early Study
  12. CROI 2016: High STI Rates Among Gay Men on PrEP Supports More Frequent Monitoring
  13. CROI 2016: Rapid Rise in PrEP Awareness in U.S. Gay Men, But Only 5% Have Used PrEP
  14. CROI 2016: PopART Shows Feasibility of Reaching 90-90-90 HIV Testing and Treatment Targets
  15. CROI 2016: Cotrimoxazole Prophylaxis Provides No Benefit for HIV-Exposed Uninfected Children
  16. CROI 2016: Tailored Support Encourages Black Gay Men to Stay on PrEP
  17. CROI 2016: Removing Clinic Barriers to Rapid ART in Uganda Enables 70% to Start on Same Day
  18. CROI 2016: Transgender People at High Risk for HIV, But Little Is Known About Prevention and Treatment
  19. CROI 2016: HIV-Related Factors Increase Risk of Stroke
  20. CROI 2016: Sofosbuvir/ Velpatasvir for Hepatitis C Can Be Administered with Most Antiretrovirals
  21. CROI 2016: START Study Shows People Starting HIV Treatment Earlier Have Better Quality of Life
  22. CROI 2016: High Levels of Chemsex and Slamsex Seen Among HIV+ Men at U.K. HIV Clinics
  23. CROI 2016: Maraviroc May Work as PrEP in a Combination, but Probably Not Alone
  24. CROI 2016: Ravidasvir Plus Sofosbuvir Demonstrates High Cure Rate for HCV Genotype 4
  25. CROI 2016: Injection-Related Indiana HIV Epidemic Is Under Control, But Vigilance Needed
  26. CROI 2016: Studies Look at Condom Use in IPERGAY French PrEP Trial
  27. CROI 2016: Early Antiretroviral Therapy Has No Impact on Cardiovascular Disease Marker
  28. CROI 2016: HIV Home Testing During Pregnancy Doubles Male Partners Who Test
  29. CROI 2016: Modest Kidney Function Decline on Truvada PrEP Supports Need for Monitoring
  30. CROI 2016: Expanding Treatment and PrEP Could Prevent 185,000 New HIV Infections, CDC Says
  31. CROI 2016: Life Expectancy of HIV-Positive People in U.S. Still Lags 13 Years Behind HIV-Negatives
  32. CROI 2016: Study Does Not Support Routine HPV Vaccination to Prevent Anal Cancer in People with HIV
  33. CROI 2016: Option B+ Cuts Mother-to-Child HIV Transmission Dramatically in Malawi
  34. CROI 2016: Large-Scale Household Tuberculosis Screening Shows Feasibility in PopART Trial
  35. CROI 2016: South Africa XDR-TB Epidemic Due to Transmission Rather than Viral Evolution
  36. CROI 2016: Experimental TLR7 Agonist Suppresses HIV-Like Virus in Monkeys After ART Interruption
  37. CROI 2016: Long-Acting Cabotegravir PrEP Injection Tolerable and Acceptable, but Dose Adjustment Needed
  38. CROI 2016: On-Demand Rectal Microbicide Gel Has Reasonable Acceptability -- Daily Less So
  39. CROI 2016: Early Antiretroviral Therapy Reduces the Risk of Infection-Related Cancers
  40. CROI 2016: Dolutegravir Is Safe and Highly Effective for Older Children with HIV
  41. CROI 2016: Botswana Close to Reaching 90-90-90 HIV Testing and Treatment Targets
  42. CROI 2016: People with HIV Considerably Overestimate Their Chances of Infecting Someone
  43. Coverage of the 2016 Conference on Retroviruses and Opportunistic Infections
  44. CROI 2016: HIV in the Brain -- New Tools and Treatment Options to Keep Your Mind Beautiful
  45. CROI 2016: Harvoni for 6 Weeks Cures HIV+ People with Acute HCV if Viral Load is Low
  46. CROI 2016: Almost-Certain Case of Truvada PrEP Failure Due to Drug Resistance Reported
  47. CROI 2016: Empirical Tuberculosis Treatment Comes Up Short Again
  48. CROI 2016: TAF/FTC Maintains Viral Suppression as Well as TDF with Less Bone and Kidney Toxicity
  49. CROI 2016: TAF PrEP Protects Monkeys, But Levels in Humans May Be Too Low
  50. CROI 2016: Long-Acting Injectable Cabotegravir + Rilpivirine Works Well as HIV Maintenance Therapy
  51. CROI 2016: Major Disparities Persist in Lifetime Risk of HIV Diagnosis in the U.S.
  52. CROI 2016: Starting HIV Treatment at First Clinic Visit Improves Outcomes in African Study
  53. CROI 2016: Tenofovir HIV Treatment Raises Risk of Broken Bones
  54. CROI 2016: Bone Density Recovers Quickly After Stopping Truvada PrEP
  55. CROI 2016: Vaginal Rings Containing Dapivirine Moderately Effective in Preventing HIV
  56. Conference on Retroviruses and Opportunistic Infections Starts Next Week in Boston
Copyright © 2023 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design